Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Barriers to Screening
3. Screening in the Era of Coronavirus Disease 2019 (COVID-19)
4. Challenges in Treatment Diagnosis
5. Biomarkers/Molecular Testing
5.1. Current Testing Paradigm and Barriers
5.2. Liquid Biopsy
5.3. Future Advancements in Biomarker Technologies
5.4. Additional Barriers to Biomarker Testing
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Coughlin, J.M.; Zang, Y.; Terranella, S.; Alex, G.; Karush, J.; Geissen, N.; Chmielewski, G.W.; Arndt, A.T.; Liptay, M.J.; Zimmermann, L.J.; et al. Understanding barriers to lung cancer screening in primary care. J. Thorac. Dis. 2020, 12, 2536–2544. [Google Scholar] [CrossRef]
- Jonas, D.E.; Reuland, D.S.; Reddy, S.M.; Nagle, M.; Clark, S.D.; Weber, R.P.; Enyioha, C.; Malo, T.L.; Brenner, A.T.; Armstrong, C.; et al. Screening for Lung Cancer with Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2021, 325, 971–987. [Google Scholar] [CrossRef] [PubMed]
- The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011, 365, 395–409. [Google Scholar] [CrossRef] [Green Version]
- Tartarone, A.; Lerose, R.; Aieta, M. Focus on lung cancer screening. J. Thorac. Dis. 2020, 12, 3815–3820. [Google Scholar] [CrossRef]
- Krist, A.H.; Davidson, K.W.; Mangione, C.M.; Barry, M.J.; Cabana, M.; Caughey, A.B.; Davis, E.M.; Donahue, K.E.; Doubeni, C.A.; Kubik, M.; et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA 2021, 325, 962–970. [Google Scholar] [PubMed]
- AFFP Lung Cancer Screening, Adult. Available online: https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/lung-cancer.html (accessed on 23 April 2022).
- NCCN Guidelines. Non-Small Cell Lung Cancer. Version 3.2022. Available online: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed on 23 April 2022).
- Richard, T.B.; Soman, A.; Thomas, C.C.; Van Frank, B.; Henley, S.J.; Gallaway, M.S.; Richardson, L.C. Screening for Lung Cancer-10 States, 2017. MMWR Morb Mortal Wkly Rep. 2020, 69, 201–206. [Google Scholar] [CrossRef]
- Jemal, A.; Fedewa, S.A. Lung Cancer Screening with Low-Dose Computed Tomography in the United States-2010 to 2015. JAMA Oncol. 2017, 3, 1278–1281. [Google Scholar] [CrossRef]
- Pham, D.; Bhandari, S.; Pinkston, C.; Oechsli, M.; Kloecker, G. Lung Cancer Screening Registry Reveals Low-dose CT Screening Remains Heavily Underutilized. Clin. Lung Cancer 2020, 21, e206–e211. [Google Scholar] [CrossRef] [PubMed]
- Sands, J.; Tammemägi, M.C.; Couraud, S.; Baldwin, D.R.; Borondy-Kitts, A.; Yankelevitz, D.; Lewis, J.; Grannis, F.; Kauczor, H.U.; von Stackelberg, O.; et al. Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation. J. Thorac. Oncol. 2021, 16, 37–53. [Google Scholar] [CrossRef]
- Robbins, H.A.; Callister, M.; Sasieni, P.; Quaife, S.L.; Cheung, L.C.; Brennan, P.; Katki, H.A.; Berg, C.D.; Baldwin, D.; Johansson, M. Benefits and harms in the National Lung Screening Trial: Expected outcomes with a modern management protocol. Lancet Respir Med. 2019, 7, 655–656. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wille, M.M.; Dirksen, A.; Ashraf, H.; Saghir, Z.; Bach, K.S.; Brodersen, J.; Clementsen, P.F.; Hansen, H.; Larsen, K.R.; Mortensen, J.; et al. Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. Am. J. Respir Crit. Care Med. 2016, 193, 542–551. [Google Scholar] [CrossRef]
- Heleno, B.; Siersma, V.; Brodersen, J. Estimation of Overdiagnosis of Lung Cancer in Low-Dose Computed Tomography Screening: A Secondary Analysis of the Danish Lung Cancer Screening Trial. JAMA Int. Med. 2018, 178, 1420–1422. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pinsky, P.F.; Gierada, D.S.; Hocking, W.; Patz, E.F., Jr.; Kramer, B.S. National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann. Int. Med. 2014, 161, 627–633. [Google Scholar] [CrossRef] [Green Version]
- Rivera, M.P.; Katki, H.A.; Tanner, N.T.; Triplette, M.; Sakoda, L.C.; Wiener, R.S.; Cardarelli, R.; Carter-Harris, L.; Crothers, K.; Fathi, J.T.; et al. Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society Statement. Am. J. Respir. Crit. Care Med. 2020, 202, e95–e112. [Google Scholar] [CrossRef]
- Haddad, D.N.; Sandler, K.L.; Henderson, L.M.; Rivera, M.P.; Aldrich, M.C. Disparities in Lung Cancer Screening: A Review. Ann. Am. Thorac. Soc. 2020, 17, 399–405. [Google Scholar] [CrossRef]
- Evans, N., III; Grenda, T.; Alvarez, N.H.; Okusanya, O.T. Narrative review of socioeconomic and racial disparities in the treatment of early stage lung cancer. J. Thorac. Dis. 2021, 13, 3758–3763. [Google Scholar] [CrossRef] [PubMed]
- Borondy Kitts, A.K. The Patient Perspective on Lung Cancer Screening and Health Disparities. J. Am. Coll. Radiol. 2019, 16, 601–606. [Google Scholar] [CrossRef] [PubMed]
- Thai, A.A.; Solomon, B.J.; Sequist, L.V. Lung cancer. Lancet 2021, 398, 535–554. [Google Scholar] [CrossRef]
- Tanner, N.T.; Gebregziabher, M.; Hughes Halbert, C.; Payne, E.; Egede, L.E.; Silvestri, G.A. Racial Differences in Outcomes within the National Lung Screening Trial. Implications for Widespread Implementation. Am. J. Respir. Crit. Care Med. 2015, 192, 200–208. [Google Scholar] [CrossRef]
- Schütte, S.; Dietrich, D.; Montet, X.; Flahault, A. Participation in lung cancer screening programs: Are there gender and social differences? A systematic review. Public Health Rev. 2018, 39, 23. [Google Scholar] [CrossRef]
- Brenner, A.T.; Malo, T.L.; Margolis, M.; Lafata, J.E.; James, S.; Vu, M.B.; Reuland, D.S. Evaluating Shared Decision Making for Lung Cancer Screening. JAMA Int. Med. 2018, 178, 1311–1316. [Google Scholar] [CrossRef] [PubMed]
- Clark, S.D.; Reuland, D.S.; Enyioha, C.; Jonas, D.E. Assessment of Lung Cancer Screening Program Websites. JAMA Int. Med. 2020, 180, 824–830. [Google Scholar] [CrossRef]
- Dubin, S.; Griffin, D. Lung Cancer in Non-Smokers. Mo Med. 2020, 117, 375–379. [Google Scholar] [PubMed]
- Siegel, D.A.; Fedewa, S.A.; Henley, S.J.; Pollack, L.A.; Jemal, A. Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States. JAMA Oncol. 2021, 7, 302–304. [Google Scholar] [CrossRef] [PubMed]
- Chen, T.Y.; Fang, Y.H.; Chen, H.L.; Chang, C.H.; Huang, H.; Chen, Y.S.; Liao, K.M.; Wu, H.Y.; Chang, G.C.; Tsai, Y.H.; et al. Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women. Sci. Rep. 2020, 10, 6774. [Google Scholar] [CrossRef] [Green Version]
- FANS (Female Asian Never Smokers) Study. Available online: https://cancer.ucsf.edu/news/2022/01/12/addressing-high-lung-cancer-rates-among-female-asian-non-smokers (accessed on 23 April 2022).
- Van Haren, R.M.; Delman, A.M.; Turner, K.M.; Waits, B.; Hemingway, M.; Shah, S.A.; Starnes, S.L. Impact of the COVID-19 Pandemic on Lung Cancer Screening Program and Subsequent Lung Cancer. J. Am. Coll. Surg. 2021, 232, 600–605. [Google Scholar] [CrossRef] [PubMed]
- Mazzone, P.J.; Gould, M.K.; Arenberg, D.A.; Chen, A.C.; Choi, H.K.; Detterbeck, F.C.; Farjah, F.; Fong, K.M.; Iaccarino, J.M.; Janes, S.M.; et al. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. Radiol. Imaging Cancer 2020, 2, e204013. [Google Scholar] [CrossRef] [Green Version]
- Hoffman, R.M.; Reuland, D.S.; Volk, R.J. The Centers for Medicare & Medicaid Services Requirement for Shared Decision-making for Lung Cancer Screening. JAMA 2021, 325, 933–934. [Google Scholar] [PubMed]
- Schreuder, A.; Scholten, E.T.; van Ginneken, B.; Jacobs, C. Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: Ready for practice? Trans. Lung Cancer Res. 2021, 10, 2378–2388. [Google Scholar] [CrossRef]
- Grenier, P.A.; Brun, A.L.; Mellot, F. The Potential Role of Artificial Intelligence in Lung Cancer Screening Using Low-Dose Computed Tomography. Diagnostics 2022, 12, 2435. [Google Scholar] [CrossRef]
- Ardila, D.; Kiraly, A.P.; Bharadwaj, S.; Choi, B.; Reicher, J.J.; Peng, L.; Tse, D.; Etemadi, M.; Ye, W.; Corrado, G.; et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat. Med. 2019, 25, 954–961. [Google Scholar] [CrossRef] [PubMed]
- Smeltzer, M.P.; Wynes, M.W.; Lantuejoul SSmeltzer, M.P.; Wynes, M.W.; Lantuejoul, S.; Soo, R.; Ramalingam, S.S.; Varella-Garcia, M.; Taylor, M.M.; Richeimer, K.; et al. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. J. Thorac. Oncol. 2020, 15, 1434–1448. [Google Scholar] [CrossRef] [PubMed]
- Liam, C.K.; Liam, Y.S.; Poh, M.E.; Wong, C.K. Accuracy of lung cancer staging in the multidisciplinary team setting. Trans. Lung Cancer Res. 2020, 9, 1654–1666. [Google Scholar] [CrossRef] [PubMed]
- Borgonje, P.E.; Andrews, L.M.; Herder, G.J.; de Klerk, J.M. Performance and Prospects of [(68)Ga]Ga-FAPI PET/CT Scans in Lung Cancer. Cancers 2022, 14, 5566. [Google Scholar] [CrossRef]
- Guibert, N.; Pradines, A.; Favre, G.; Mazieres, J. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur. Respir. Rev. 2020, 29, 190052. [Google Scholar] [CrossRef] [Green Version]
- Roosan, M.R.; Mambetsariev, I.; Pharaon, R.; Fricke, J.; Husain, H.; Reckamp, K.L.; Koczywas, M.; Massarelli, E.; Bild, A.H.; Salgia, R. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest 2021, 160, 1095–1107. [Google Scholar] [CrossRef]
- Duffy, M.J.; O’Byrne, K. Tissue and Blood Biomarkers in Lung Cancer: A Review. Adv. Clin. Chem. 2018, 86, 1–21. [Google Scholar]
- Papadopoulou, E.; Tsoulos, N.; Tsantikidi, K.; Metaxa-Mariatou, V.; Stamou, P.E.; Kladi-Skandali, A.; Kapeni, E.; Tsaousis, G.; Pentheroudakis, G.; Petrakis, D.; et al. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. PLoS ONE 2019, 14, e0226853. [Google Scholar] [CrossRef] [Green Version]
- Beer, T.M. Novel blood-based early cancer detection: Diagnostics in development. Am. J. Manag. Care 2020, 26, S292–S299. [Google Scholar]
- Liu, M.C.; Oxnard, G.R.; Klein, E.A.; Swanton, C.S.M.C.C.; Seiden, M.V.; Liu, M.C.; Oxnard, G.R.; Klein, E.A.; Smith, D.; Richards, D.; et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 2020, 31, 745–759. [Google Scholar] [CrossRef]
- Klein, E.A.; Richards, D.; Cohn, A.; Tummala, M.; Lapham, R.; Cosgrove, D.; Chung, G.; Clement, J.; Gao, J.; Hunkapiller, N.; et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann. Oncol. 2021, 32, 1167–1177. [Google Scholar] [CrossRef]
- Lennon, A.M.; Buchanan, A.H.; Kinde, I.; Warren, A.; Honushefsky, A.; Cohain, A.T.; Ledbetter, D.H.; Sanfilippo, F.; Sheridan, K.; Rosica, D.; et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 2020, 369, eabb9601. [Google Scholar] [CrossRef]
- Pellini, B.; Chaudhuri, A.A. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated with Curative Intent. J. Clin. Oncol. 2022, 40, 567–575. [Google Scholar] [CrossRef]
- Shende, P.; Augustine, S.; Prabhakar, B.; Gaud, R.S. Advanced multimodal diagnostic approaches for detection of lung cancer. Expert Rev. Mol. Diagn. 2019, 19, 409–417. [Google Scholar] [CrossRef] [PubMed]
- Seijo, L.M.; Peled, N.; Ajona, D.; Boeri, M.; Field, J.K.; Sozzi, G.; Pio, R.; Zulueta, J.J.; Spira, A.; Massion, P.P.; et al. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. J. Thorac. Oncol. 2019, 14, 343–357. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carvalho, A.S.; Moraes, M.C.S.; Hyun Na, C.; Fierro-Monti, I.; Henriques, A.; Zahedi, S.; Bodo, C.; Tranfield, E.M.; Sousa, A.L.; Farinho, A.; et al. Is the Proteome of Bronchoalveolar Lavage Extracellular Vesicles a Marker of Advanced Lung Cancer? Cancers 2020, 12, 3450. [Google Scholar] [CrossRef]
- Zahedi, S.; Carvalho, A.S.; Ejtehadifar, M.; Beck, H.C.; Rei, N.; Luis, A.; Borralho, P.; Bugalho, A.; Matthiesen, R. Assessment of a Large-Scale Unbiased Malignant Pleural Effusion Proteomics Study of a Real-Life Cohort. Cancers 2022, 14, 4366. [Google Scholar] [CrossRef]
- Arya, S.K.; Bhansali, S. Lung cancer and its early detection using biomarker-based biosensors. Chem. Rev. 2011, 111, 6783–6809. [Google Scholar] [CrossRef] [PubMed]
- Young, K.; da Cunha Santos, G.; Card, P.; Leighl, N. The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective. Cancer Cytopathol. 2019, 127, 72–78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pennell, N.A.; Arcila, M.E.; Gandara, D.R.; West, H. Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. Am. Soc. Clin. Oncol. Educ. Book 2019, 39, 531–542. [Google Scholar] [CrossRef]
- Pishvaian, M.J.; Blais, E.M.; Bender, R.J.; Rao, S.; Boca, S.M.; Chung, V.; Hendifar, A.E.; Mikhail, S.; Sohal, D.P.; Pohlmann, P.R.; et al. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open 2019, 2, 505–515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rajurkar, S.; Mambetsariev, I.; Pharaon, R.; Leach, B.; Tan, T.; Kulkarni, P.; Salgia, R. Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. J. Clin. Med. 2020, 9, 1870. [Google Scholar] [CrossRef] [PubMed]
Total Percentage Screened in US in 2016 | 2.0% 9 |
---|---|
Percentage screened in West in 2016 | 1.1% (Region ranked 3rd out of 4 regions in terms of number of eligible smokers for screening) 9 |
Percentage screened in South in 2016 | 1.7% (Region ranked 1st out of 4 regions in terms of number of eligible smokers for screening) 9 |
Percentage screened in Midwest in 2016 | 2.1% (Region ranked 2nd out of 4 regions in terms of number of eligible smokers for screening) 9 |
Percentage screened in Northeast in 2016 | 3.9% (Region ranked 4th out of 4 regions in terms of number of eligible smokers for screening) 9 |
Mean number of LDCT screening centers per state in 2017 | 34 48 |
Percentage of adults without lung cancer screening center within 30 miles (persons aged 55 to 79 in 2017) | 14.9% 48 |
Percentage of adults without lung cancer screening center within 30 min drive (persons aged 55 to 79 in 2017) | 28.1% 48 |
Percentage of urban residents with access to LDCT screening center within 30 miles in 2017 | 93.7% 48 |
Percentage of urban residents with access to LDCT screening center within 30 min drive in 2017 | 83.2% 48 |
Percentage of rural residents with access to LDCT screening center within 30 miles in 2017 | 47.5% 48 |
Percentage of rural residents with access to LDCT screening center within 30 min drive in 2017 | 22.2% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zarinshenas, R.; Amini, A.; Mambetsariev, I.; Abuali, T.; Fricke, J.; Ladbury, C.; Salgia, R. Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer. Cancers 2023, 15, 1595. https://doi.org/10.3390/cancers15051595
Zarinshenas R, Amini A, Mambetsariev I, Abuali T, Fricke J, Ladbury C, Salgia R. Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer. Cancers. 2023; 15(5):1595. https://doi.org/10.3390/cancers15051595
Chicago/Turabian StyleZarinshenas, Reza, Arya Amini, Isa Mambetsariev, Tariq Abuali, Jeremy Fricke, Colton Ladbury, and Ravi Salgia. 2023. "Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer" Cancers 15, no. 5: 1595. https://doi.org/10.3390/cancers15051595
APA StyleZarinshenas, R., Amini, A., Mambetsariev, I., Abuali, T., Fricke, J., Ladbury, C., & Salgia, R. (2023). Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer. Cancers, 15(5), 1595. https://doi.org/10.3390/cancers15051595